WINTON GROUP Ltd Buys New Position in Tandem Diabetes Care, Inc. $TNDM

WINTON GROUP Ltd bought a new stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 44,244 shares of the medical device company’s stock, valued at approximately $972,000. WINTON GROUP Ltd owned approximately 0.07% of Tandem Diabetes Care as of its most recent SEC filing.

Several other large investors have also bought and sold shares of TNDM. Freestone Grove Partners LP bought a new position in Tandem Diabetes Care during the third quarter valued at about $22,706,000. Assenagon Asset Management S.A. bought a new position in Tandem Diabetes Care during the fourth quarter valued at about $26,988,000. BNP Paribas Financial Markets boosted its stake in Tandem Diabetes Care by 468.5% during the fourth quarter. BNP Paribas Financial Markets now owns 1,248,481 shares of the medical device company’s stock valued at $27,442,000 after buying an additional 1,028,866 shares in the last quarter. ArrowMark Colorado Holdings LLC boosted its stake in Tandem Diabetes Care by 36.7% during the third quarter. ArrowMark Colorado Holdings LLC now owns 3,691,198 shares of the medical device company’s stock valued at $44,811,000 after buying an additional 991,649 shares in the last quarter. Finally, Jennison Associates LLC boosted its stake in Tandem Diabetes Care by 42.3% during the fourth quarter. Jennison Associates LLC now owns 2,021,376 shares of the medical device company’s stock valued at $44,430,000 after buying an additional 601,260 shares in the last quarter.

Wall Street Analyst Weigh In

TNDM has been the subject of several research reports. Morgan Stanley raised their target price on Tandem Diabetes Care from $23.00 to $25.00 and gave the company an “equal weight” rating in a research note on Monday, March 2nd. Citigroup reaffirmed a “neutral” rating and set a $17.00 target price (down from $22.00) on shares of Tandem Diabetes Care in a research note on Thursday, May 28th. Truist Financial reaffirmed a “buy” rating and set a $31.00 target price (down from $35.00) on shares of Tandem Diabetes Care in a research note on Monday, May 11th. Lake Street Capital raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $50.00 target price for the company in a research note on Monday, February 23rd. Finally, UBS Group reaffirmed a “neutral” rating and set a $22.00 target price (up from $17.00) on shares of Tandem Diabetes Care in a report on Friday, February 20th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.84.

Tandem Diabetes Care Stock Performance

TNDM opened at $17.61 on Wednesday. The firm has a market capitalization of $1.21 billion, a P/E ratio of -12.58 and a beta of 1.58. The stock’s 50 day moving average price is $17.92 and its two-hundred day moving average price is $20.34. The company has a quick ratio of 3.07, a current ratio of 3.58 and a debt-to-equity ratio of 4.54. Tandem Diabetes Care, Inc. has a 12-month low of $9.98 and a 12-month high of $29.65.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Thursday, May 7th. The medical device company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.16. The firm had revenue of $247.22 million for the quarter, compared to analyst estimates of $240.41 million. Tandem Diabetes Care had a negative return on equity of 53.88% and a negative net margin of 9.20%.The company’s revenue was up 5.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.66) EPS. On average, equities analysts forecast that Tandem Diabetes Care, Inc. will post -0.74 earnings per share for the current year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.